Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Chỉ hiển thị Multimedia
Abrocitinib effectively controls AD regardless of dosing regimen
03 Aug 2023
bởiAudrey Abella
In patients with moderate-to-severe atopic dermatitis (AD), flexible dosing of abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, appeared as beneficial as the continuous high-dose regimen. This was demonstrated in a post hoc analysis of two studies from the JADE* clinical development programme.
Abrocitinib effectively controls AD regardless of dosing regimen
03 Aug 2023
Integrated analysis supports long-term efficacy of ritlecitinib for alopecia areata
28 Jul 2023
bởiAudrey Abella
An integrated analysis of the pivotal phase IIb/III ALLEGRO and phase III ALLEGRO-LT studies demonstrated the long-term efficacy of the oral JAK3/TEC family kinase inhibitor ritlecitinib for alopecia areata (AA).
Integrated analysis supports long-term efficacy of ritlecitinib for alopecia areata
28 Jul 2023
Ustekinumab shows efficacy in Asians with plaque psoriasis
14 Jul 2023
bởiStephen Padilla
Asian patients with moderate to severe plaque psoriasis may benefit from ustekinumab therapy, which has been shown to be both safe and effective in a Singapore study.